Search for: "PAR PHARMACEUTICALS"
Results 221 - 240
of 303
Sorted by Relevance
|
Sort by Date
1 Nov 2017, 4:00 am
TD Canada Trust, 2017 SCC 51 [1] A pharmaceutical company was the victim of a fraudulent cheque scheme implemented by one of its employees. [read post]
21 Nov 2008, 11:36 am
You can separately subscribe to the Pharma & Biotech edition of the IP Think Tank Global Week in Review by subscribing by email, or selecting ‘all posts’ or ‘Pharma, Biotech & Chem’ for the RSS option at the Subscribe page: [duncanbucknell.com] Highlights this week included: Plavix (Clopidogrel) – Canada: Supreme Court upholds selection patents: Apotex v Sanofi-Synthelabo Canada et al (Pharmacapsules @ Gowlings) (Hal… [read post]
9 Sep 2011, 6:13 am
We recently reported on the Par Pharmaceuticals lawsuit, and the Pittsburgh Business Times reports that two subsidiaries of Mylan were not pursued by the federal government (a sign that the case is not strong against those two entities). [read post]
8 Jul 2009, 7:04 am
– CAFC decision in Agilent Techs v Affymetrix concerning claims pertaining to ‘microarray hybridization’ (Gray on Claims) US: Counterclaims dismissed in Alzheimer’s Institute/ Mayo patent licensing dispute over transgenic mice (Patent Docs) Products (Tavanic) Levofloxacin – UK: EWCA upholds decision that Daiichi’s Levofloxacin patent and SPC both invalid: Generics (UK) Ltd v Daiichi Pharmaceutical Co Ltd and Daiichi… [read post]
5 Apr 2007, 5:39 am
Par Pharmaceutical, Inc., 2006 WL 901657, at *4 (W.D. [read post]
12 Aug 2009, 3:03 am
Among other things, the article cites a source as saying that nonfinancial public companies still have $24 billion (par value) of ARS on their books. [read post]
24 Aug 2020, 12:00 am
In general, proceedings in the field of mechanical engineering will be classified as “regular” and proceedings in the field of pharmaceuticals as “complex”. [read post]
20 Mar 2009, 2:05 am
Ill. 1987).Indiana: Ortho Pharmaceutical Corporation v. [read post]
9 Apr 2009, 7:52 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US CAFC clarifies obviousness standard in context of cDNA cloning invention: In re Kubin (Holman's Biotech IP Blog) (Patent Docs) (Hal Wegner) (Philip Brooks' Patent Infringement Updates) (Patently-O) (Patent Docs) Xigris (Drotrecogin alfa) –US: CAFC: Pioneering claims require more expansive written description: Ariad v Eli… [read post]
28 Jan 2010, 4:51 am
Older adults are also less able to prevent pharmaceutical errors be [read post]
31 Oct 2018, 5:09 pm
As I noted here, Allergan, Teva Pharmaceuticals, and Endo International (whose Par Pharmaceuticals unit is caught up in the investigation) – all three companies that have been identified by name in connection with the alleged generic drug price-fixing conspiracy – previously were hit with securities class action lawsuit related to the price-fixing investigation. [read post]
11 Feb 2013, 6:00 am
Of course self-insured employers do not set out to get sub-par results from the adjusters. [read post]
21 Jul 2017, 8:33 am
" Par Pharm., 773 F.3d at 1195-96. [read post]
4 Nov 2017, 5:47 am
The case concerned the use of ribavirin for the manufacturer of a pharmaceutical composition for treating a specific sub-group (the G1N-subgroup) of HCV patients suffering with chronic hepatitis. [read post]
16 Aug 2019, 3:07 pm
Philosophically her work is on par with such stellar exemplars in the philosophical examination of psychoanalysis as Marcia Cavell, Ilham Dilman, Sebastian Gardner, Jonathan Lear, A.O. [read post]
14 Jan 2020, 6:00 am
The U.K. will confront tough demands from Washington on issues such as pharmaceutical pricing, food standards, and environmental issues. [read post]
18 Jan 2018, 9:34 am
WARNING LETTERMark BaumImprimis Pharmaceuticals Inc.12264 El Camino Real, Suite 350San Diego, CA 92130Dear Mr. [read post]
2 Jan 2013, 11:54 am
Par Pharmaceutical (Sept. 28, 2012). [read post]
23 Mar 2023, 10:37 am
.); and 3. a functional factor for the identification of the data holders who should make health data available for secondary use (Recital 40 EHDS and Art. 33 par. 3 EHDS). [read post]
28 Oct 2009, 5:00 am
The possibility always existed that the debt would trade at below par or that the company would lack the cash to repurchase the instruments. [read post]
